Felix Fischbach

@felixfischbach.bsky.social

Clinician Scientist | Neuroimmunology Focused on #celltherapies for neuroimmunological disease and regulation of neuronal translation during #inflammation induced #neurodegeneration

Among 16 patients with refractory neurologic autoimmune disorders, lentiviral CD19 CAR T-cell therapy was associated with manageable side effects, complete B-cell depletion, and preliminary clinical improvement across disease groups. Full trial results: https://nej.md/4zPPwbD

A figure showing the clinical outcome measures after treatment, including scores on the Expanded Disability Status Scale (EDSS; range, 0 to 10, with higher scores indicating greater disability) in patients with MS or MOGAD (left), Manual Muscle Testing 8 (MMT-8) scores (range, 0 to 150, with higher scores indicating stronger muscles) in those with IIM or gMG (middle), and scores on the Quantitative Myasthenia Gravis (QMG) scale (range, 0 to 39; higher scores indicate greater disease activity) in those with gMG (right).

Check out our latest research on how a neuron-immune axis modulates peripheral immune responses during multiple sclerosis. We discovered it by exploring pregnancy-associated immune modulation in multiple sclerosis. Special thanks to Jana Sonner and Audrey Kahn: www.nature.com/articles/s41...

A GDF-15–GFRAL axis controls autoimmune T cell responses during neuroinflammation - Nature Immunology

Here the authors show that endogenous or therapeutically delivered GDF-15 activates brainstem neurons that trigger splenic β-adrenergic signaling. This, in turn, suppresses autoreactive T cells and re...

nature.com